WC2022 Programme Overview

(updated at 8 June 2022)
Programme is subject to change without prior notice.

Day 1Sunday, 12 Jun 2022 Day 2Monday, 13 Jun 2022 Day 3Tuesday, 14 Jun 2022 Day 4Wednesday, 15 Jun 2022 Day 5Thursday, 16 Jun 2022 Day 6Friday, 17 Jun 2022

DAY 3 Tuesday, 14 Jun 2022

Download PDF Programme Download PDF Detailed Programme

Activity	Heliconia Main Ballroom	Hibiscus 3602	Hibiscus 3604	Hibiscus 3606	Hibiscus 3702	Hibiscus 3704	Hibiscus 3706
0730 onwards	Registration Cassia Main Ballroom, Level 3
0830 - 1000	0830-0915 Meet the Expert: Genscript	Education Session 7 IFMBE CED Benefit of our Extensive Hacking Repository Collection for Global Research	Special Symposium 25 Organ Doses from Diagnostic and Therapeutic Procedures: Necessity and Feasibility	Special Symposium 26 Material Systems for Quantitative Mechanobiology	Oral Session 3.1 Bioelectronics and Electroceuticals	Education Session 8 Advances in In-Vivo Dosimetry for External Beam Radiotherapy (Sun Nuclear)	Education Session 9 18th ACOMP Course: Quality & Safety in SBRT MLC Tracking: Clinical Rationale, Clinical Experience, Guidelines & Future Directions
1000 - 1030	Coffee Break, Exhibition and Poster Viewing Cassia Main Ballroom, Level 3
1030 - 1100	Plenary Lecture 5 Innovative High-Throughput Tissue Engineering Strategies for Better Understanding and Optimizing Biomaterial/Cell InteractionsProf Rui Reis, Portugal
1100 - 1130	Plenary Lecture 6 (SEAFOMP John Cameron Memorial Lecture): Photon-counting-detector CT Technology and Clinical ApplicationsProf Cynthia H. McCollough, USA
1230 - 1330	Lunch Symposium Satellite: Elekta Instrument AB	Lunch Break, Exhibition and Poster Viewing Cassia Main Ballroom, Level 3
1330 - 1500	IOMP Awardee PresentationM Curie Award Harold Johns Medal	Education Session 10 Clinical Engineers Advocating for Single Global Nomenclature	Special Symposium 28 Frontiers of Multifunctional Biomedical Ultrasound Technologies	Special Symposium 29 Diagnostic Reference Levels	Special Symposium 30 AI in Radiotherapy	Oral Session 3.2 Radiation Therapy Physics	Oral Session 3.3 Bio-Micro/Nanotechnologies
1500 - 1530	Coffee Break Area, Exhibition and Poster Viewing Cassia Main Ballroom, Level 3
1530 - 1700	IUPESM Awardee Oral Presentation	Special Symposium 31 Ethical Issues in Biomedical Engineering	Oral Session 3.4 Radiobiology	Special Symposium 32 Advances and Current Trends in Hybrid PET Imaging	Oral Session 3.5 Diagnostic and Interventional Radiology Physics	Oral Session 3.6 Radiation Therapy Physics	Oral Session 3.7 Bio-Micro/Nanotechnologies
1700 - 1830	1730-1945IFMBE General Assembly	Special Symposium 33 Science Diplomacy for Future Advancement in Medical Physics	Special Symposium 34 Digital Transformation and Artificial Intelligence: Data Driven Decision Making for the Care and Health of the Future	Special Symposium 35 Are Many Patients Getting High Doses Over 100 mSv and What Can Be Done? [IOMP-IAEA-WHO-DITTA]	Oral Session 3.8 Nuclear Medicine and Molecular Imaging Physics	Oral Session 3.9 Radiation Therapy Physics	Oral Session 3.10 Bio-Micro/Nanotechnologies
2030 - 2230	IFMBE Presidential & CoS Reception By Invitation only

Previous Day Next Day

Title	Protein engineering for a “bio-better” next-generation therapeutic
Details	Date: 14 Jun 2022 Time: 0830 - 1000hrs
Faculty	Dr. Edward Wong, Product Manager, GenScript Asia Pacific (Singapore) Dr. Edward Wong is the product manager in GenScript. He completed his Ph.D. degree from University of Adelaide. He worked as a Post Doctoral fellow at National Cancer Centre Singapore for 3 years and he had successfully reported the predictive factors for genetic screening of BRCA1 and BRCA2. He also reported the importance of genetic testing for 25 breast cancer-predisposition genes using NGS technology. Both of his works were reported in PlosOne and npj Genomic Medicine.
Synopsis	Antibodies play a major role in supporting the life sciences from different aspects, including the use of antibody in detection assay and diagnostic tests or for therapeutic purposes. With the advent of advanced technology, we can now reach the targets that previously known as “undruggable” due to the availability of high diversity of antibodies. Nonetheless, to find the right candidates among the high diversity of antibodies can be laborious and time-consuming. Furthermore, the researcher would have experienced a number of challenges, including the missing out on good binders, poor antibody library coverage, throughout the discovery and development workflow. Several attempts have been made to address these challenges. Among these attempts, the affinity maturation is an important strategy in antibody optimization to generate safe and efficacious second-generation therapeutics. The recent development of synthetic biology provides the breakthrough that allow the researchers to precisely define and control the synthesis of high-diversity domain libraries. The optimization process usually requires several rounds of the mutant library construction and screening in order to isolate the top ideal candidate. The benefit of identifying the improved antibody, in a higher specificity and affinity, can help to enhance a higher success rate in the clinic while reducing in cost to the patient due to a smaller and infrequent dosing.
Objectives	A) How we can rapidly identify and validate a diverse repertoire of high-affinity antibodies? B) How we can further improve the binding affinity of the antibody while reducing the screening burden during the optimization process?

WC2022 Programme Overview

DAY 3 Tuesday, 14 Jun 2022

Meet the Expert